neutropenia
Neutrophils play an important role in the host defense against bacterial invasion. Primarily they act by prevention and containment of bacterial and fungal infections. In addition they are important mediators of inflammatory responses. Approximately 1 · 10 9 neutrophils/kg are produced in the bone marrow daily [2] . Major characteristics of these neutrophils are the potential to travel through the body to sites of injury, to phagocytose and destroy the intruders.
Neutropenia (generally defined as an absolute granulocyte count of <500/mm 3 ) can be divided into disorders secondary to abnormalities of production, distribution, or secondary to rapid use or turnover of cells in peripheral blood. Of these, production anomalies are the most frequent.
A more helpful classification based on production problems classifies neutropenia in forms related to intrinsic hematological disorders and secondary forms caused by extrinsic factors, including drugs, radiation, autoimmune disorders, and infections [3] (see Table 1 ).
Drug-induced neutropenia is probably the most frequent cause of neutropenia [4, 5] . As radiotherapy, cytotoxic drugs predictably cause neutropenia, depending on dose and the individual characteristics of the drug (like class and target cell) by affecting production.
neutropenic fever and cytotoxic drugs
Neutropenia and fever is major dose-limiting effect of many cytotoxic drugs. The incidence of neutropenic fever is directly related to depth and duration of the neutropenia [6] . This depends on the intensity of regimens used and patient-and disease-related factors [7] . This may be and is currently used to classify patients in risk groups [8] [9] [10] [11] .
Febrile neutropenia is generally defined as a rise in axillary temperature to above 38.5°C for more than one hour while having an absolute neutrophil count of less than 0.5 · 10 9 /l. Other definitions are also used like 38°C during one to four hours [7, [12] [13] [14] .
In the majority of patients with neutropenia, fever may be the only symptom of infection. If treated with corticosteroids, fever may even be absent.
Since the early eighties of the previous century it was recognized that, among other explanations, early treatment with broad spectrum antibiotics of neutropenic fever patients greatly reduced the mortality rate [15] [16] [17] . This mortality was mainly due to gram-negative sepsis. Nowadays, there is a shift from gram-negative to gram-positive infections [18] . In a recent study the incidence rates of gram-positive microbes seem to increase with an unexpected increase in mortality rates [18] . However, one still has to consider that in the majority of patients blood cultures remain negative [19] .
Incidence rates vary enormously, depending on patient groups described, and is generally much higher in patients treated for acute leukemias or stem cell transplantation. In nonleukemic patients leucopenia (World Health Organisation (WHO) grade 4) varies between 2 and 28%, febrile neutropenia up to 10 to 57%, infections (WHO grades 3 or 4) up to 16% but death in febrile neutropenia is less than 7% [20] . In chemo-naïve patients these incidence rates are lower.
Neutropenic fever generally results in hospitalization, with its related economic burden. Therefore, there should be a strong urge to prevent these costs.
As described before, patients can be discriminated according to their risk of medical complications due to the febrile neutropenia.
Low-risk patients are generally younger than 65 years with a good general condition; the underlying disease is known and controlled; there are no signs of pneumonia, sepsis or central nervous system (CNS) there is no central venous catheter and no high levels of C-reactive protein; and short duration of expected neutropenia [21] . The Multinational Association for Supportive Care in Cancer (MASCC) has developed a scoring system to identify low-risk patients with cancer and febrile neutropenia [22] .
prevention of neutropenia and febrile neutropenia in cancer treatment
Although not all patients with neutropenia develop neutropenic fever, neutropenia is a significant risk factor for infections. Disruption of defense mechanisms may increase the likelihood for infections, as is the duration and depth of the neutropenia.
Several factors have been identified, which can be influenced and lower the likelihood of developing infection. Here, we will discuss prevention of neutropenia and, if not possible, decreasing its depth or duration, or other measures which may prevent neutropenic fever.
less chemotherapy-dose reduction
As cytotoxic drugs, and sometimes radiation or the combination of both are the main causative factors for neutropenia, dose reduction may prevent neutropenia. However, for many drugs there is a significant dose-response relationship. So, decreasing doses may decrease efficacy, which has been demonstrated in several malignancies like breast cancer and Hodgkin's disease. This makes dose reduction in patients with a curative treatment less attractive. In these patients growth factor support should be considered (see next paragraph).
In case of palliative treatment indications, one should clearly consider the option of dose reduction and whether the palliative potential can be reached with this dose reduction.
growth factors; primary prophylaxis
Since the introduction of the hematopoietic growth factors granulocyte macrophage colony stimulating factor (GM-CSF) (Sargramostim), granulocyte colony stimulating factor (G-CSF) (Lenograstim and Filgrastim) and pegylated Filgrastim many trials have been performed to assess the value of these drugs in preventing neutropenia and neutropenic fever and, also, in enabling dose adherence.
It is now well established that growth factors can prevent up to 50% of occurrences of neutropenic fever, however, without clear benefits in survival or response [23] [24] [25] [26] [27] . This translates in an overtreatment of at least 50% of patients, without benefit and decreasing costs-benefit.
If the likelihood of developing neutropenic fever increases over 40% growth factor support may be considered [20, 28] . This also may apply to situations where dose reduction (necessary for neutropenic fever in previous cycles) is deemed detrimental for treatment outcome [20, 28] . The later procedure is called secondary prophylaxis.
Several data suggest that the likelihood of neutropenic fever is highest during the first cycles of chemotherapy [29, 30] . This may be an argument for primary prophylaxis with or without antibiotics [31] . This issue is not completely settled yet. Primary prophylaxis may also be considered in patients with reduced marrow reserve, human immunodeficiency virus infection, active infections, or reduced performance status [20, 28] .
In patients with a high-risk for neutropenic fever like those with bone marrow transplantation growth factor support can be helpful [20, 28] . Although not recommended in the European Society for Medical Oncology (ESMO) guidelines, growth factor support may be used in acute myeloid leukemia (AML) trials not to reduce infections but to increase efficacy of chemotherapy [32] .
growth factors; secondary prophylaxis
Patients with neutropenic fever have an increased risk to develop the same problem during subsequent therapy. If dose reduction is detrimental for the patient and other etiological factors for neutropenia have been excluded or not improved (e.g. bone marrow infiltration) secondary prophylaxis may be considered [20, 28] . In these patients the cost-benefit balance is in favor for growth factor support.
antibiotics Prophylactic antibiotic therapy to prevent infections in potentially neutropenic patients has a broad application, especially in the high-dose regimens in hematological malignancies.
This approach shows a debatable benefit [23, 24] . Arguments against prophylactic antibiotic use include but are not limited to the potential emergence of resistance against antibiotics. However, in two recently published randomized trials, levofloxacin had not only a significant impact on the reduction of fever, probable infection and hospitalization in low-risk patients with lymphoma and solid tumors [12, 33] but also in high-risk patients with profound and prolonged neutropenia [12] .
treatment of febrile neutropenia
Although mortality has significantly been reduced, neutropenic fever still is a significant burden for the patient but also for the society, due to the high economic costs of hospitalization. Although many very effective antibiotics are available for the treatment of neutropenic fever many trials have been performed to improve results and to assess cost-efficacy of available treatment options.
It is clearly necessary to divide the patients with neutropenic fever into risk groups. Generally these have been defined based on depth and duration of neutropenia or other clinical risk factors [21] or systems like the MASCC Scoring System [22] .
antibiotics in febrile neutropenia
The rapid initiation of antibiotics in neutropenic fever has lead to a significant improvement of the prognosis over the past decades [15] [16] [17] . Nowadays, it is increasingly clear that this observation is correct for high-risk patients, but may be less correct for low-risk neutropenic patients. Several trials have been published presenting data in low-risk patients, including a meta-analysis [13, 14, [34] [35] [36] . Oral antibiotics consisting of quinolones (plus in many trials amoxicillin-clavulanate) is safe and at least as effective as standard intravenous therapy [14, 35, 36] .
In high-risk neutropenic patients, especially in relation to stem cell transplantation or anti-leukemia therapy, patients are generally hospitalized and treatment is still consisting of broad spectrum intravenous antibiotics [37] . Best approach for these patients is based on local protocols, which take local microbial resistance data into account. These protocols are beyond the scope of this overview.
growth factors plus antibiotics in febrile neutropenia
Growth factors are able to speed up recovery of neutrophils in patients with neutropenia. This characteristic has been exploited in several trials in patients with neutropenic fever, where growth factors have been added to antibiotic therapy. Recently, a meta-analysis of 13 trials was published [38] . Conclusions from this analysis are that overall mortality was not influenced significantly by the use of growth factors. A marginally significant result was obtained in reducing infection-related mortality (odds ratio = 0.51; 95% CI, 0.26 to 1.00; P = 0.05). In addition they had shorter length of hospitalization and (of course) a shorter time to neutrophil recovery. In trials designed to assess costs in relation to efficacy the outcome was not favorable due to the high costs of the growth factors in some [39] but cost-effective in other [40] .
application of growth factors
Originally two growth factors have been developed: G-CSF and GM-CSF. Currently almost all treatments are with G-CSF, largely because of a relatively lack of side effects compared to GM-CSF. Apart from G-CSF (Lenograstim or Filgrastim) which both have to be administered daily, currently also a once per cycle growth factor is available (peg-filgrastim). Generally the use of 5 lg/kg/day of G-CSF subcutaneously 24-72 h after the last day of chemotherapy until sufficient/stable absolute neutrophil count (ANC) recovery is recommended. It is not necessary to treat patients till they achieve a target ANC of >10 · 10 9 /l. Peg-filgrastim, injected subcutaneously as a single dose of either 100 lg/kg (individualized) or of a total dose of 6 mg (general approach), is considered equally effective as the other G-CSF's [41, 42] .
There is some evidence that G-CSF is better not be used during radiotherapy to the chest due to increased rate of complications and death. Also, some data suggest that severe thrombocytopenia may occur when growth factors are given immediately prior to, or simultaneously with, chemotherapy [43] .
conclusions and recommendations (Tables 3 and 4) Neutropenia, and especially neutropenic fever, is a medical emergency. Certainly also in cancer patients alternative diagnoses other than treatment-induced neutropenia should be considered. Prevention of neutropenia by decreasing treatment doses may be an option in a small subset of patients. In patients where optimal dosing is the goal, prophylaxis with either antibiotics or the combination of antibiotics plus growth factor support may be a good alternative. Patients who present with neutropenic fever should be treated with antibiotics. The choice (oral or intravenous) may depend on their individual risk profile. The use of growth factors in the prevention or treatment of neutropenic fever is still debated.
further reading ESMO guidelines on growth factor use [20] . ASCO guidelines on growth factor use [28] . 
